Globe Roche Logo

cobas® Cdiff

Definitive results in under 20 minutes with the cobas® Liat® System

Accurately detect one of the most common healthcare-associated infections

cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System brings real-time polymerase chain reaction (PCR) technology to near patient testing.

Address the growing threat of Clostridium difficile (C. difficile) and keep a closer eye on your at-risk patients. cobas® Cdiff facilitates earlier intervention for more effective infection control and transmission prevention, while delivering the performance that clinical confidence demands.

Limit the spread of infection with real-time PCR C. difficile detection

Detect C. diff from unformed stool specimens, deliver definitive results to inform timely treatment, and take appropriate measures for isolation and prevention to limit the spread of infection.

  • 20 minute turnaround time for definitive results when they’re needed most
  • Simplified workflow with less than 1 minute of hands-on time and easy result interpretation
  • Ideal for STAT or out-of-hours locations

Intended Use:

The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is an automated, qualitative in vitro diagnostic test that uses real-time polymerase chain reaction (PCR) for the detection of the toxin B (tcdB) gene of toxigenic Clostridium difficile in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI). The cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System is intended for use as an aid in the diagnosis of CDI in humans in conjunction with clinical and epidemiological risk factors.

This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Reference:

  1. cobas® Cdiff [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2017.